The Latest Breaking News from FDA

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

A special House panel looking into the government's coronavirus response says the Trump White House tried to pressure U.S. health experts into reauthorizing the anti-malaria drug hydroxychloroquine that had been discredited as a COVID-19 treatment

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…

After a long delay, the Food and Drug Administration issued final regulations Aug. 16, 2022, for over-the-counter hearing aids. The final rule is effective 60 days from its publication, meaning that consumers could see OTC hearing aids hitting the shelves of community pharmacies nationwide by October 2022.

The FDA approved over-the-counter hearing aids, which will be available for those with “mild to moderate” hearing loss. These experts delve into what you should know.

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT

An estimated 85 percent of Black smokers use menthols, according to the FDA, compared with 30 percent of white smokers. 

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 72.8% to close at $2.16 on Monday as the stock continued to see momentum despite the company last week announcing it is not aware of any developments that would explain the recent surge.

Pfizer has submitted data on its bivalent COVID-19 booster shot that specifically targets the latest omicron subvariants. If authorized, the company says the shots could be ready as soon as September.